AI summary & key facts
In the FLOWPROMOTE randomized trial (JAMA Cardiology), 40 mg atorvastatin shrank total plaque by about 14% over 18 months, while 40 mg rosuvastatin plus 10 mg ezetimibe shrank it by about 21%, measured with before-and-after coronary CT angiography. A shared summary adds that 104 newly diagnosed coronary disease patients took part, LDL fell to about 43 in the combination arm, and soft plaque fell about 28%. The trial was small and measured plaque, not heart attacks.
- 104 patients newly diagnosed with coronary artery disease, 18 months
- Total plaque: -14% atorvastatin 40 mg vs -21% rosuvastatin 40 mg + ezetimibe 10 mg
- Soft plaque fell about 28% in the combination group; LDL about 43 mg/dL
- Lower LDL achieved meant more regression
In the recently published FLOWPROMOTE randomized trial:
40mg atorvastatin shrank total plaque by 14% in 18 months.
40mg rosuvastatin + 10mg ezetimibe shrank it by 21% in the same time.
This was proven with full before-and-after CT angiography of the coronary arteries.
#statinreverseHD #statinsHD #ezetimibeHD #flowpromoteHD #ezetimibereverseHD #reverseHD
Dangerous, rupture-prone heart plaque shrank in 98% of patients on this combo. 🫀
A new trial in JAMA Cardiology (FLOWPROMOTE, published Oct 30) followed 104 people newly diagnosed with coronary artery disease for 18 months.
Half took a standard statin. Half took high-dose rosuvastatin plus ezetimibe.
In the combo group, LDL dropped to around 43. Total plaque went down about 21%, and the soft, dangerous plaque went down about 28%. Plaque shrank in both groups, and the lower LDL went, the more it shrank.
What this study can’t tell us yet: it was small, it measured plaque on CT scans instead of heart attacks, and everyone was just starting treatment. Still, it fits years of research showing lower LDL means less plaque and lower risk.
Your move: know your LDL number, and ask your doctor what your target should be.